XKRX
141080
Market cap1.99bUSD
Oct 08, Last price
73,300.00KRW
1D
-8.94%
1Q
-39.07%
Jan 2017
106.77%
IPO
194.97%
Name
LegoChem Biosciences Inc
Chart & performance
P/E
—
P/S
18.87
EPS
—
Div yield, %
—
Shrs. gr., 5y
9.98%
Rev. gr., 5y
23.44%
Revenues
141.55b
+12.43%
Net income
-74.28b
L
CFO
-124.53b
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
LigaChem Biosciences, Inc. specializes in the development and manufacturing of a broad spectrum of medical solutions, encompassing pharmaceuticals, medical devices, and essential healthcare supplies. Their extensive product offerings include various therapeutic agents such as antibiotics, anti-coagulants, and oncology treatments, alongside cutting-edge antibody-drug conjugates and protein-drug conjugates. Established on May 2, 2006, the company's headquarters are situated in Daejeon, South Korea.
Key people
Yong Ju Kim
Chief Executive Officer, Director · since 2021
Jun Su Kim
Internal Auditor · since 2024
Rodrigo Soto
Chief Medical Officer · since 2024
Yeong Rak Cho
Vice President, Director
Director · since 2024
Se Jin Park
President, Director · since 2023
Seung Ho Lee
Non-Executive Independent Director · since 2024
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||